Samabriva

Samabriva

Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Samabriva is a private, pre-revenue biotechnology company founded in 2011, headquartered in Paris and Amiens, France, with a biomanufacturing facility in Liège, Belgium. The company has developed a unique, patented bioproduction platform based on plant hairy root cultures grown in bioreactors, enabling the contained, year-round production of complex biomolecules. Operating primarily as a platform and service provider (CDMO/CFO model), Samabriva targets pharmaceutical and biotech clients seeking to outsource the production of plant-derived active ingredients, recombinant proteins, and virus-like particles (VLPs) with greater supply chain control and a reduced environmental footprint. Recent milestones include opening a new production facility and forming strategic partnerships, such as with Généthon for AAV vector production.

Digital HealthRespiratory

Technology Platform

Proprietary, automated bioproduction platform using plant hairy root cultures grown in bioreactors for the contained, sustainable production of secondary metabolites, recombinant proteins, and VLPs.

Opportunities

The growing demand for sustainable, resilient biomanufacturing and the acute need for scalable, cost-effective production of gene therapy vectors (like AAVs) present significant market opportunities.
Samabriva's technology is well-positioned to address supply chain vulnerabilities and the high costs associated with traditional biologics production.

Risk Factors

Key risks include the challenge of convincing the conservative pharmaceutical industry to adopt a novel production platform, potential technical hurdles in scaling the process to the largest commercial volumes, and the need to gain full regulatory acceptance for therapeutics produced via this method.

Competitive Landscape

Samabriva competes with established mammalian and microbial CDMOs, as well as other innovative bioproduction platforms using plant cell cultures or whole-plant molecular farming. Its differentiation lies in the specific use of hairy root cultures for their genetic stability and productivity in a fully contained bioreactor system.